Ts-104

Phase 1

TTwoStep Therapeutics, Inc.

Ts-104 is one of 6 therapeutic programs targeting NSCLC (Non-small Cell Lung Cancer). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

NSCLC (non-Small Cell Lung Cancer)Recruiting

NSCLC (non-Small Cell Lung Cancer)Phase 1

Recruiting

Competition

Competitive Landscape

6 competitors in NSCLC (non-Small Cell Lung Cancer)

#DrugCompanyPhaseTrials

Gavreto

RRigel Pharmaceuticals

Approved

1 2

Beyfortus

BeiGene

Phase 2

1 3

PD-1/PD-L1 Inhibitor

SSecond Affiliated Hospital of Soochow University

Phase 3

1 4

Surufatinib

HHutchison Medipharma Limited

Phase 2

1 5

Concurrent Chemotherapy

SSun Yat-sen University

Phase 2

1 6

Ts-104

TTwoStep Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

NSCLC (non-Small Cell Lung Cancer)

NCT07814248

Clinical

Trials by Indication[1]

NSCLC (Non-small Cell Lung Cancer)1 trial

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Advanced Solid Tumors

Recruiting·TTwoStep Therapeutics, Inc.·Phase 1·NCT07814248·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ts-104. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ts-104. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — TwoStep Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: TTwoStep Therapeutics, Inc.

Ts-104

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

NSCLC (Non-small Cell Lung Cancer)1 trial

References

Drug Info

Quick Facts

Related News